Pressing Questions to Address With Ongoing Research With CAR T-Cell Therapy in Myeloma

Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, explore key unanswered questions guiding ongoing CAR T-cell therapy research in multiple myeloma. They discuss areas such as earlier-line use, durability of response, retreatment strategies, and combination approaches. Merz and Bellerive conclude by emphasizing how continued research will shape the future integration of CAR T-cell therapy into myeloma care.